title: Fluorescein Angiography Versus Optical Coherence Tomography Angiography in Macular Telangiectasia Type I Treated With Bevacizumab Therapy.
abstract: This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) after a 7-year bevacizumab (Avastin; Genentech, South San Francisco, CA) treatment course. OCTA allowed for clear visualization of most telangiectasias and aneurysms in the deep capillary plexus, with only few microvascular dilatations in the superficial plexus. In addition, areas of capillary dropout in the superficial and deep vascular plexa located near telangiectasias were documented on OCTA. Serial FA demonstrated reduced number of aneurysms and telangiectasias at the 7-year mark compared to baseline. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:263-266.].
authors.forename: Nicolas A
authors.initials: NA
authors.lastname: Yannuzzi
authors.forename: Ninel Z
authors.initials: NZ
authors.lastname: Gregori
authors.forename: Luiz
authors.initials: L
authors.lastname: Roisman
authors.forename: Nisha
authors.initials: N
authors.lastname: Gupta
authors.forename: Brian E
authors.initials: BE
authors.lastname: Goldhagen
authors.forename: Raquel
authors.initials: R
authors.lastname: Goldhardt
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D002196:Capillaries / Q000473:pathology; D005451:Fluorescein Angiography / Q000379:methods*; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000098:blood supply* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D058456:Retinal Telangiectasis / Q000175:diagnosis* / Q000188:drug therapy; D012171:Retinal Vessels / Q000473:pathology*; D041623:Tomography, Optical Coherence / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab